The frequent development of cellular resistance to cisplatin in cancer patients is a serious
limitation for clinical drug therapy. However, cisplatin resistance is incompletely understood …

Previously we reported that liposomal cisplatin (CDDP) overcomes CDDP resistance of
ovarian A2780cis cancer cells (Krieger et al., Int. J. Pharm. 389, 2010, 10–17). Here we find …

Purpose: Cisplatin and its platinum derivatives are first-line chemotherapeutic agents in the
treatment of ovarian cancer; however, treatment is associated with tumor resistance and …

The clinical application of cisplatin to treat solid tumours is often limited by the development
of tumour cell resistance against this cytostatic agent. Although liposomal carriers of cisplatin …

Ovarian cancer is one of the most common malignant tumors of the female reproductive
system. The majority of patients with advanced ovarian cancer are mainly treated with …

Cisplatin and its analogues have been most frequently used for treatment of human cancer
including ovarian cancer. Most advanced ovarian cancer which was fatal before introduction …

Liposomes have been considered as promising, but passive carriers in medical sciences to
mediate a controlled transport of a drug cargo to target sites or into target cells. Here, we …

Ovarian cancer is an aggressive and lethal cancer usually treated by cytoreductive surgery
followed by chemotherapy. Unfortunately, after an initial response, many patients relapse …

Ovarian cancer is one of the most common gynecological cancers. Recently, there is
increase in incidence of ovarian cancer not only India but also worldwide. Ovarian cancer …

Background Resistance to current chemotherapeutic agents is a major cause of therapy
failure in ovarian cancer patients, but the exact mechanisms leading to the development of …